A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves

This study aimed to determine whether a dosage adjustment of enoxaparin during pregnancy to maintain a peak anti-Xa of 1.0 to 1.2 U/mL, was safe for women with mechanic prosthetic heart valves (MPHV). It was performed at Charlotte Maxeke Johannesburg Academic Hospital from 2007 to 2009. The method used fifteen women with MPHVs were treated with enoxaparin with a dosage adjustment to achieve a peak anti-Xa of 1.0 to 1.2 U/mL. Main outcomes measured were prosthetic valve thrombosis, bleeding, and maternal mortality. This resulted in no maternal mortality. None of the women developed valvular thrombosis during pregnancy. In all, 2 women developed epistaxis and another developed spotting per vaginum. The authors concluded that data showed that enoxaparin may be administered safely during pregnancy to pregnant women with MPHV when there was dosage adjustment throughout pregnancy to maintain an anti-Xa of 1.0 to 1.2 U/mL.

Authors: Saeed, Chitsike Rufaro; Frank, Jacobson Barry; Pravin, Manga; Aziz, Rhemtula Haroun; Serasheini, Moodley; Dominique, Toweel Gabrielle. ;Full Source: Clinical and Applied Thrombosis/Hemostasis 2011, 17(4), 313-319 (Eng) ;